Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06240390
Other study ID # 22109-2
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 1, 2024
Est. completion date December 1, 2024

Study information

Verified date January 2024
Source Universidad Europea de Canarias
Contact Eduardo Martín, MsC
Phone 699553677
Email edumartin@hotmail.es
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

the goal of this clinical trial is to compare in cancer patients: Is ultrasound-guided percutaneous neuromodulation useful for Anterior Knee Pain relief in cancer patients? Participants will receive treatments of ultrasound-guided percutaneous neuromodulation and pharmacological treatment Researchers will compare ultrasound-guided percutaneous neuromodulation versus pharmacological treatment to see if Anterior Knee Pain is reduced


Description:

Unhealthy lifestyles, an aging population and increased life expectancy increase the likelihood of cancer. Knee pain is one of the most common symptoms that cause functional incapacity, which requires the search and improvement of its assessment, prevention and treatment tools. Physiotherapists are currently using ultrasound-guided Percutaneous Neuromodulation clinically. It is an easy process to perform, non-invasive, safe and economical. Traditional therapies have been and will continue to be useful. The decrease in manufacturing costs of assessment tools such as ultrasound and neuromodulator treatment in recent years has made the acquisition of these equipment as intervention tools economical. This is because they have been shown to be useful for improving function and reducing pain. Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects. In order to improve these symptoms, it is essential to have an objective knowledge of the changes produced by neuromodulation and to be able to measure the variation of pain experienced by patients. It has been demonstrated in recent years that assessment tools such as ultrasound and myotonometer are very useful, safe and non-invasive procedures, both have been consolidated as assessment tools that can evaluate changes and analyze the contractile properties of soft tissue quickly and safely. There are abundant literature on this subject. Therefore, researchers suggest conducting research that improves and provides new data on the efficacy and effectiveness of treatment of ultrasound-guided percutaneous neuromodulation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date December 1, 2024
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: The proposed inclusion criteria for the study are as follows: - Age between 18 and 65. - Pain in the front of the knee. - Taking drug therapy for lower-extremity pain. - Diagnosis of painful pathology in the anterior aspect of the knee secondary oncologic. Exclusion Criteria: The exclusion criteria are: - Traumatic history - Have had any type of analgesic treatment in the last 4 weeks (clinical, physical or orthostatic) - No need for drug treatment within the last 30 days of study initiation.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Ultrasound-guided percutaneous neuromodulation (NMP)
Epte Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system. It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as transcranial direct current stimulation. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies. The Epte® Bipolar System device has an CE Health Certificate
Drug:
pharmacological treatment by Opioids
Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects.

Locations

Country Name City State
Spain Centro RED Tenerife Santa Cruz De Tenerife

Sponsors (1)

Lead Sponsor Collaborator
Universidad Europea de Canarias

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Numerical Pain Rating Scale (NPRS) Anterior Knee Pain changes The Numerical Pain Rating Scale (NPRS) is a unique 11-point numeric scale that measures pain and instructs patients in clinical practice to choose a scale number from 0 to 10 with 0 for "no pain" and 10 for "worst pain possible." Its use is widely used in diseases of the knee or lower limbs, such as iliotibial girdle syndrome, sacroiliac joint dysfunction, plantar fasciitis or acute knee pain treated with microcurrents. It has also been used to treat shoulder pain in patients who have had surgery for breast cancer 12 weeks
Primary Victorian Institute of Sport Assessment-Patella (VISA-P) The VISA-P questionnaire is used for assessing the severity of symptoms in individuals with patellar tendinopathy, the term pain refers to the specific area of the patellar tendon, to mark its intensity patients should mark taking into account that 0 represents absence of pain and 10 the maximum pain imagined by the patient. In the analysis of patellar tendon pathology has already been used in repeated articles 12 weeks
Primary The OKS (Oxford Knee Score) questionnaire for knee function. The Oxford Knee Score is a well-known tool for assessing quality of life in patients with Osteo Arthritis of the knee (OA). The OKS is a self-administered questionnaire that the patient can answer in face-to-face interviews or send by mail once completed. It contains 12 questions with 5 possible answers each aimed at evaluating the perception of the quality of life of the patient in the last four weeks. Each answer receives a score of 0 to 4, where 4 is the best possible result. After the sum, you get a total score ranging from 0 to 48, where 48 is the best possible result. The Spanish adaptation of the OKS questionnaire is a reliable tool to evaluate the perception of health-related quality of life of patients with knee osteoarthritis (OA). 12 weeks
Primary The Lower Limb Functional Index (LLFI). The questionnaire contains a number of phrases (25 in total) that patients use to describe problems on their legs. Evaluating only the last few days if a phrase describes you should check that box, you can also mark it partially and if not you should leave it blank. Finally, an LLFI score is obtained where the functional index of the lower extremities is determined. The LLFI consists of 25 items with three-point response options (Yes = 1 point), ("In part" or "half" 1/2 points) and (NO Points = 0). With a gross score range of 0 to 25 points. Takes approximately 2 minutes. The score is calculated by simply adding the answers together and multiplying them by four minus 100 to convert them into a percentage scale or maximum loss of function. The LLFI questionnaire in Spanish proved to be suitable for assessing the functionality of the lower limbs and viable for the evaluation of the condition and deterioration of the lower limbs in clinical and research settings 12 weeks
Primary Borg's Rating Perceived Exertion (RPE) questionnaire for perceived fatigue. Borg created Borg's 15-point RPE scale. The modified RPE scale is 6 to 20 points. The level of physical exertion or perceived exertion is measured using the Borg 15-point RPE scale. A significant correlation was found between heart rate and Borg RPE of 15 points. In addition, this scale is believed to be a useful and cost-effective tool for monitoring exercise intensity.80 Patients in clinical practice are instructed to choose a number from the scale and assess their total effort during endurance training. A score of six indicates lack of effort, or rest, and a score of twenty indicates maximum effort, or the most exhausting exercise 12 weeks
Primary Pressure pain threshold The intensity of pain can provide relevant information, until now the measurement of pain was carried out subjectively for this reason there are efforts to develop devices to measure the intensity of painful stimuli objectively. Severity of pain also affects the patient's treatment strategy and goals because pain can cause incapacitation. Thus, several researchers have focused their efforts on creating pain-measuring devices called algometers. A pressure pain threshold (UDP) is usually used to measure this sensation. It is applied at the above point and measured in Kg/cm2. 12 weeks
See also
  Status Clinical Trial Phase
Suspended NCT05067257 - Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer Phase 2
Recruiting NCT06160323 - Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer N/A
Terminated NCT04872556 - Evaluation of the Effect of Laser Acupuncture on Taxane Acute Pain Syndrome Patients N/A
Recruiting NCT05236647 - Subcutaneous Versus Intravenous Morphine When Switching From Oral to Parenteral Route in Palliative Cancer Patients Phase 3
Not yet recruiting NCT04782206 - S3 Root Pulsed Radiofrequency Added to Superior Hypogstric Plexus Block N/A
Not yet recruiting NCT06240377 - Effectiveness of NMP and TDCS vs Pharmacological Treatment in Cancer Patients With Lower Limb Pain N/A
Recruiting NCT05450419 - The Role of Vitamin D3 Supplementation in Advanced Cancer Patients With Pain N/A
Recruiting NCT06101849 - Chronic Cancer Pain Management Program N/A
Recruiting NCT05299047 - Fluoroscopic Anterior Approach Versus Ultrasound Guided Superior Hypogastric Plexus Neurolysis in Cancer Pelvic Pain Phase 2
Withdrawn NCT04572776 - Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain Phase 3
Recruiting NCT03297723 - Effectiveness of a Patient Therapeutic Education Program in Improving Pain Management